S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
Birthplace of the atomic bomb braces for its biggest mission since the top-secret Manhattan Project
The single greatest medical breakthrough of all time? (Ad)
MILAN FASHION PHOTOS: Naomi Campbell stuns at Dolce&Gabbana in collection highlighting lingerie
Speaker McCarthy is giving hard-right Republicans what they want. But it never seems to be enough.
The single greatest medical breakthrough of all time? (Ad)
At UN, African leaders say enough is enough: They must be partnered with, not sidelined
Minnesota's would-be head of cannabis regulation quits amid reports she sold illegal products
The single greatest medical breakthrough of all time? (Ad)
After climate summit, California Gov. Gavin Newsom faces key decisions to reduce emissions back home
Leading Egyptian opposition politician targeted with spyware, researchers find
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
Birthplace of the atomic bomb braces for its biggest mission since the top-secret Manhattan Project
The single greatest medical breakthrough of all time? (Ad)
MILAN FASHION PHOTOS: Naomi Campbell stuns at Dolce&Gabbana in collection highlighting lingerie
Speaker McCarthy is giving hard-right Republicans what they want. But it never seems to be enough.
The single greatest medical breakthrough of all time? (Ad)
At UN, African leaders say enough is enough: They must be partnered with, not sidelined
Minnesota's would-be head of cannabis regulation quits amid reports she sold illegal products
The single greatest medical breakthrough of all time? (Ad)
After climate summit, California Gov. Gavin Newsom faces key decisions to reduce emissions back home
Leading Egyptian opposition politician targeted with spyware, researchers find
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
Birthplace of the atomic bomb braces for its biggest mission since the top-secret Manhattan Project
The single greatest medical breakthrough of all time? (Ad)
MILAN FASHION PHOTOS: Naomi Campbell stuns at Dolce&Gabbana in collection highlighting lingerie
Speaker McCarthy is giving hard-right Republicans what they want. But it never seems to be enough.
The single greatest medical breakthrough of all time? (Ad)
At UN, African leaders say enough is enough: They must be partnered with, not sidelined
Minnesota's would-be head of cannabis regulation quits amid reports she sold illegal products
The single greatest medical breakthrough of all time? (Ad)
After climate summit, California Gov. Gavin Newsom faces key decisions to reduce emissions back home
Leading Egyptian opposition politician targeted with spyware, researchers find
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
Birthplace of the atomic bomb braces for its biggest mission since the top-secret Manhattan Project
The single greatest medical breakthrough of all time? (Ad)
MILAN FASHION PHOTOS: Naomi Campbell stuns at Dolce&Gabbana in collection highlighting lingerie
Speaker McCarthy is giving hard-right Republicans what they want. But it never seems to be enough.
The single greatest medical breakthrough of all time? (Ad)
At UN, African leaders say enough is enough: They must be partnered with, not sidelined
Minnesota's would-be head of cannabis regulation quits amid reports she sold illegal products
The single greatest medical breakthrough of all time? (Ad)
After climate summit, California Gov. Gavin Newsom faces key decisions to reduce emissions back home
Leading Egyptian opposition politician targeted with spyware, researchers find

Rocket Pharmaceuticals (RCKT) Stock Forecast, Price & News

$20.40
-0.44 (-2.11%)
(As of 09/22/2023 ET)
Compare
Today's Range
$20.13
$21.16
50-Day Range
$15.07
$24.05
52-Week Range
$11.78
$24.65
Volume
985,535 shs
Average Volume
2.24 million shs
Market Capitalization
$1.64 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$49.45

Rocket Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
142.4% Upside
$49.45 Price Target
Short Interest
Bearish
8.99% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.81
Upright™ Environmental Score
News Sentiment
0.75mentions of Rocket Pharmaceuticals in the last 14 days
Based on 3 Articles This Week
Insider Trading
Selling Shares
$108,381 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($3.15) to ($2.74) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.53 out of 5 stars

Medical Sector

194th out of 965 stocks

Pharmaceutical Preparations Industry

76th out of 456 stocks


RCKT stock logo

About Rocket Pharmaceuticals (NASDAQ:RCKT) Stock

Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a multi-platform biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia. The company also has a clinical stage in vivo adeno-associated virus program for Danon disease, a multi-organ lysosomal-associated disorder leading to early death due to heart failure. It has license agreements with Fred Hutchinson Cancer Research Center; Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas, Centro de Investigacion Biomedica En Red, and Fundacion Instituto de investigacion Sanitaria Fundacion Jimenez Diaz; UCL Business PLC; The Regents of the University of California; and REGENXBIO, Inc. The company is headquartered in Cranbury, New Jersey.

RCKT Price History

RCKT Stock News Headlines

Wall Street Legend Warns "Mass Bank Run" is Coming
Man who predicted 2023 bank run warns it could soon get worse. Get out of cash and into a new vehicle 50 years in the making. Click here to learn more.
Watch SHOCKING Footage of AI Facility with Ties to Elon Musk
I recently traveled more than 3,000 miles and shot this video outside what could end up being Elon Musk’s biggest secret. Most people don’t know about this facility, but it could be the most important AI project in the world. What’s happening inside these walls is so important that our government has declared it a matter of national security.
Rocket Pharmaceuticals stock takes flight on FDA agreement
Why Is Rocket Pharmaceuticals (RCKT) Stock Up 35% Today?
Analyst Expectations for Rocket Pharmaceuticals's Future
See More Headlines
Receive RCKT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Rocket Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

RCKT Company Calendar

Last Earnings
8/10/2023
Today
9/24/2023
Next Earnings (Estimated)
11/02/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:RCKT
Employees
240
Year Founded
2018

Price Target and Rating

Average Stock Price Forecast
$49.45
High Stock Price Forecast
$75.00
Low Stock Price Forecast
$34.00
Forecasted Upside/Downside
+142.4%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
12 Analysts

Profitability

Net Income
$-221,860,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$6.47 per share

Miscellaneous

Free Float
55,482,000
Market Cap
$1.64 billion
Optionable
Optionable
Beta
1.16

Social Links

(Almost) Everything You Need To Know About The EV Market Cover

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report

Key Executives

  • Dr. Gaurav D. Shah M.D. (Age 48)
    CEO & Director
    Comp: $1.05M
  • Ms. Kinnari Patel M.B.A. (Age 44)
    MBA, Pharm.D., PharmD, Pres & COO
    Comp: $849.93k
  • Mr. John C. Militello CPA (Age 50)
    CPA, VP, Sr. Controller, Treasurer, Principal Accounting Officer & Interim Principal Financial Officer
    Comp: $501.42k
  • Mr. Mayo Pujols (Age 54)
    Chief Technical Officer & Exec. VP
    Comp: $649.71k
  • Mr. Raj Prabhakar M.B.A. (Age 49)
    Sr. VP & Chief Bus. Officer
    Comp: $619.13k
  • Mr. Martin Louis Wilson J.D. (Age 47)
    Gen. Counsel, Chief Compliance Officer & Sr. VP
  • Kevin Giordano
    Director of Corp. Communications
  • Ms. Isabel Carmona J.D.
    Sr. VP & Chief HR Officer
  • Mr. Jonathan Schwartz M.D. (Age 58)
    Chief Gene Therapy Officer & Sr. VP of Clinical Devel.
  • Dr. Gayatri R. Rao J.D.
    M.D., Chief Devel. Officer of LVV & Sr. VP













RCKT Stock - Frequently Asked Questions

Should I buy or sell Rocket Pharmaceuticals stock right now?

12 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Rocket Pharmaceuticals in the last year. There are currently 12 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" RCKT shares.
View RCKT analyst ratings
or view top-rated stocks.

What is Rocket Pharmaceuticals' stock price forecast for 2023?

12 analysts have issued 1 year target prices for Rocket Pharmaceuticals' shares. Their RCKT share price forecasts range from $34.00 to $75.00. On average, they predict the company's stock price to reach $49.45 in the next year. This suggests a possible upside of 142.4% from the stock's current price.
View analysts price targets for RCKT
or view top-rated stocks among Wall Street analysts.

How have RCKT shares performed in 2023?

Rocket Pharmaceuticals' stock was trading at $19.57 at the beginning of the year. Since then, RCKT stock has increased by 4.2% and is now trading at $20.40.
View the best growth stocks for 2023 here
.

When is Rocket Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 2nd 2023.
View our RCKT earnings forecast
.

How were Rocket Pharmaceuticals' earnings last quarter?

Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) released its quarterly earnings data on Thursday, August, 10th. The biotechnology company reported ($0.82) EPS for the quarter, missing the consensus estimate of ($0.81) by $0.01. During the same period last year, the firm earned ($0.83) EPS.

What ETFs hold Rocket Pharmaceuticals' stock?
What other stocks do shareholders of Rocket Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Rocket Pharmaceuticals investors own include Nymox Pharmaceutical (NYMX), Pfizer (PFE), SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), Amarin (AMRN), Energy Transfer (ET), Micron Technology (MU), VBI Vaccines (VBIV), Vaxart (VXRT) and Alibaba Group (BABA).

What is Rocket Pharmaceuticals' stock symbol?

Rocket Pharmaceuticals trades on the NASDAQ under the ticker symbol "RCKT."

Who are Rocket Pharmaceuticals' major shareholders?

Rocket Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional investors include BlackRock Inc. (6.38%), State Street Corp (3.95%), Goldman Sachs Group Inc. (1.79%), Dimensional Fund Advisors LP (1.66%), Geode Capital Management LLC (1.47%) and Perceptive Advisors LLC (1.45%). Insiders that own company stock include Gaurav Shah, Gotham Makker, John Militello, Jonathan David Schwartz, Kinnari Patel and Rtw Investments, Lp.
View institutional ownership trends
.

How do I buy shares of Rocket Pharmaceuticals?

Shares of RCKT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Rocket Pharmaceuticals' stock price today?

One share of RCKT stock can currently be purchased for approximately $20.40.

How much money does Rocket Pharmaceuticals make?

Rocket Pharmaceuticals (NASDAQ:RCKT) has a market capitalization of $1.64 billion. The biotechnology company earns $-221,860,000.00 in net income (profit) each year or ($3.34) on an earnings per share basis.

How many employees does Rocket Pharmaceuticals have?

The company employs 240 workers across the globe.

How can I contact Rocket Pharmaceuticals?

Rocket Pharmaceuticals' mailing address is 350 FIFTH AVENUE SUITE 7530, NEW YORK NY, 10118. The official website for the company is www.rocketpharma.com. The biotechnology company can be reached via phone at (609) 659-8001, via email at investors@rocketpharma.com, or via fax at 646-224-9585.

This page (NASDAQ:RCKT) was last updated on 9/24/2023 by MarketBeat.com Staff

My Account -